CoChat

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Nicotinamide riboside (NR) is in wide use as an NAD + precursor vitamin. Here we determine the time and dose-dependent effects of NR on blood NAD + metabolism in humans. We report that human blood NAD + can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one individual, and that oral NR elevates mouse hepatic NAD + with distinct and superior pharmacokinetics to those of nicotinic acid and nicotinamide. We further show that single doses of 100, 300 and 1,000 mg of NR produce dose-dependent increases in the blood NAD + metabolome in the first clinical trial of NR pharmacokinetics in humans. We also report that nicotinic acid adenine dinucleotide (NAAD), which was not thought to be en route for the conversion of NR to NAD + , is formed from NR and discover that the rise in NAAD is a highly sensitive biomarker of effective NAD + repletion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12948

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The NAD+ metabolome. NAD+ is synthesized by salvage of the vitamin precursors, NA, Nam and NR, or from tryptophan in the de novo pathway. NAD+ can be reduced to NADH, phosphorylated to NADP+ or consumed to Nam. Nam can also be methylated and oxidized to waste products. NAAD was not thought to be a precursor of NAD+ from NR.
Figure 1 The NAD+ metabolome. NAD+ is synthesized by salvage of the vitamin precursors, NA, Nam and NR, or from tryptophan in the de novo pathway. NAD+ can be reduced to NADH, phosphorylated to NADP+ or consumed to Nam. Nam can also be methylated and oxidized to waste products. NAAD was not thought to be a precursor of NAD+ from NR.CC BY · PubMed Central
Figure 2 Elevation of the PBMC NAD+ metabolome by oral NR in a 52 year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. PBMCs were prepared from blood collected before the first dose (0 h), at seven time points after the first dose (0.6, 1, 1.4, 2.7, 4.1, 7.7 and 8.1 h), before second dose (23.8 h) and 24 h after the seventh dose (167.6 h). Concentrations (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me2PY; g, Me4PY; h, NAAD; i, ADPR) are with respect to whole blood volumes. The data indicate that the NAD+ metabolome—with the exception of Nam and NAAD—is elevated by the 4.1 time point post ingestion. Whereas PBMC Nam was never elevated by NR, NAAD was elevated by the next time point. NAD+ and NAAD remained elevated 24 h after the last dose.
Figure 2 Elevation of the PBMC NAD+ metabolome by oral NR in a 52 year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. PBMCs were prepared from blood collected before the first dose (0 h), at seven time points after the first dose (0.6, 1, 1.4, 2.7, 4.1, 7.7 and 8.1 h), before second dose (23.8 h) and 24 h after the seventh dose (167.6 h). Concentrations (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me2PY; g, Me4PY; h, NAAD; i, ADPR) are with respect to whole blood volumes. The data indicate that the NAD+ metabolome—with the exception of Nam and NAAD—is elevated by the 4.1 time point post ingestion. Whereas PBMC Nam was never elevated by NR, NAAD was elevated by the next time point. NAD+ and NAAD remained elevated 24 h after the last dose.CC BY · PubMed Central
Figure 3 Elevation of the plasma NAD+ metabolome by oral NR in a 52-year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. Plasma samples were prepared from blood collected before the first dose (0 h), at seven time points after the first dose (0.6, 1, 1.4, 2.7, 4.1, 7.7 and 8.1 h), before second dose (23.8 h) and 24 h after the seventh dose (167.6 h). Concentrations (a, Nam; b, MeNam; c, Me2PY; d, Me4PY) are with respect to whole blood volumes. The data indicate that plasma MeNam, Me4PY and Me2PY are strongly elevated by oral NR. No phosphorylated species were found in plasma.
Figure 3 Elevation of the plasma NAD+ metabolome by oral NR in a 52-year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. Plasma samples were prepared from blood collected before the first dose (0 h), at seven time points after the first dose (0.6, 1, 1.4, 2.7, 4.1, 7.7 and 8.1 h), before second dose (23.8 h) and 24 h after the seventh dose (167.6 h). Concentrations (a, Nam; b, MeNam; c, Me2PY; d, Me4PY) are with respect to whole blood volumes. The data indicate that plasma MeNam, Me4PY and Me2PY are strongly elevated by oral NR. No phosphorylated species were found in plasma.CC BY · PubMed Central
Figure 4 Elevation of the urinary NAD+ metabolome by oral NR in a 52-year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. Urine was collected before the first dose, in three collection fractions in the first 12 h and before the second and fifth daily dose. Concentrations (a, Nam; b, MeNam; c, Me2PY; d, Me4PY) are normalized to urinary creatinine. The data indicate that urinary MeNam, Me4PY and Me2PY are the dominant metabolites elevated by oral NR. No phosphorylated species were found in urine.
Figure 4 Elevation of the urinary NAD+ metabolome by oral NR in a 52-year-old male. A healthy 52-year-old male ingested 1,000 mg NC Cl daily for 1 week. Urine was collected before the first dose, in three collection fractions in the first 12 h and before the second and fifth daily dose. Concentrations (a, Nam; b, MeNam; c, Me2PY; d, Me4PY) are normalized to urinary creatinine. The data indicate that urinary MeNam, Me4PY and Me2PY are the dominant metabolites elevated by oral NR. No phosphorylated species were found in urine.CC BY · PubMed Central
Figure 5 NR elevates hepatic NAD+ metabolism distinctly with respect to other vitamins. Either saline (orange, n=3 per time point) or equivalent moles of NR (black, n=3 per time point), NA (blue, n=4 per time point) and Nam (green, n=4 per time point) were administered to male C57Bl6/J mice by gavage. To control for circadian effects, gavage was performed at indicated times before a common ∼2 pm tissue collection. In the left panels, the hepatic concentrations (pmol per mg of wet tissue weight) of each metabolite (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me4PY; g, NA; h, NAMN; i, NAAD; and j, ADPR) are shown as a function of the four gavages. The excursion of each metabolite as a function of saline gavage is shown in orange; as a function of NR in black; as function of Nam in green; and NA in blue. In the right panels, the baseline-subtracted 12-hour AUCs are shown. (left) ‡P value<0.05; ‡‡P value<0.01; ‡‡‡P value <0.001 Nam versus NA; †P value<0.05; ††P value<0.01; †††P value<0.001 Nam versus NR; #P value<0.05; ##P value<0.01; ###P value<0.05 NA versus NR; (right) *P value<0.05; **P value<0.01; ***P value <0.001. The data indicate that NR produces greater increases in NAD+ metabolism than Nam or NA with distinctive kinetics, that Nam is disadvantaged in stimulation of NAD+-consuming activities, and that NAAD is surprisingly produced after oral NR administration.
Figure 5 NR elevates hepatic NAD+ metabolism distinctly with respect to other vitamins. Either saline (orange, n=3 per time point) or equivalent moles of NR (black, n=3 per time point), NA (blue, n=4 per time point) and Nam (green, n=4 per time point) were administered to male C57Bl6/J mice by gavage. To control for circadian effects, gavage was performed at indicated times before a common ∼2 pm tissue collection. In the left panels, the hepatic concentrations (pmol per mg of wet tissue weight) of each metabolite (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me4PY; g, NA; h, NAMN; i, NAAD; and j, ADPR) are shown as a function of the four gavages. The excursion of each metabolite as a function of saline gavage is shown in orange; as a function of NR in black; as function of Nam in green; and NA in blue. In the right panels, the baseline-subtracted 12-hour AUCs are shown. (left) ‡P value<0.05; ‡‡P value<0.01; ‡‡‡P value <0.001 Nam versus NA; †P value<0.05; ††P value<0.01; †††P value<0.001 Nam versus NR; #P value<0.05; ##P value<0.01; ###P value<0.05 NA versus NR; (right) *P value<0.05; **P value<0.01; ***P value <0.001. The data indicate that NR produces greater increases in NAD+ metabolism than Nam or NA with distinctive kinetics, that Nam is disadvantaged in stimulation of NAD+-consuming activities, and that NAAD is surprisingly produced after oral NR administration.CC BY · PubMed Central
Figure 6 Rising NAAD is a more sensitive biomarker of elevated tissue NAD+ metabolism than is NAD+. Male C57Bl6/J mice were intraperitoneally injected either saline (n=8) or NR Cl (500 mg kg−1 body weight) (n=6) for 6 days. Livers and hearts were freeze-clamped and prepared for metabolomic analysis. Concentrations of NAD+ metabolites (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me4PY; g, NAMN; h, NAAD; i, ADPR) in heart and liver are presented in pmol mg−1 of wet tissue weight. Data were analysed using a two-way analysis of variance followed by a Holm–Sidak multiple comparisons test. *P value<0.05, **P value<0.01, ***P value<0.001. NR strikingly increased NAAD even in the heart, a tissue in which NAD+ metabolism was increased without an increase in steady-state NAD+ concentration.
Figure 6 Rising NAAD is a more sensitive biomarker of elevated tissue NAD+ metabolism than is NAD+. Male C57Bl6/J mice were intraperitoneally injected either saline (n=8) or NR Cl (500 mg kg−1 body weight) (n=6) for 6 days. Livers and hearts were freeze-clamped and prepared for metabolomic analysis. Concentrations of NAD+ metabolites (a, NMN; b, NAD+; c, NADP+; d, Nam; e, MeNam; f, Me4PY; g, NAMN; h, NAAD; i, ADPR) in heart and liver are presented in pmol mg−1 of wet tissue weight. Data were analysed using a two-way analysis of variance followed by a Holm–Sidak multiple comparisons test. *P value<0.05, **P value<0.01, ***P value<0.001. NR strikingly increased NAAD even in the heart, a tissue in which NAD+ metabolism was increased without an increase in steady-state NAD+ concentration.CC BY · PubMed Central
Figure 7 NR contributes directly to hepatic NAAD. Double-labelled NR was orally administered to mice. At indicated times after gavage, mice (n=3) were euthanized and livers freeze-clamped for isotopic enrichment analysis. Data are plotted as pmol mg−1 of wet tissue weight. At the 2 h time point, hepatic NAD+ (a) shows 54% incorporation of M+1 and M+2 species, indicating that more than half of the NAD+ is turned over before there is a rise in steady-state NAD+. At 2 h, hepatic NADP+ (b) shows 32% incorporation of label(s) from ingested NR. At all time points, half or more of hepatic Nam (c) and MeNam (d) carries an NR-derived label, indicating that NR has driven rapid NAD+ synthesis and consumption. At 2 h after gavage, 45% of hepatic NAAD (e) incorporates NR-derived label(s). At 2 h, hepatic NAD+ (a), NADP+ (b) and NAAD (e) pools incorporate 5, 6 and 8% of double-labelled NR indicating that NR is a direct precursor of all three metabolites and excluding the possibility that the NR-driven increase in NAAD is due to inhibition of de novo synthesis.
Figure 7 NR contributes directly to hepatic NAAD. Double-labelled NR was orally administered to mice. At indicated times after gavage, mice (n=3) were euthanized and livers freeze-clamped for isotopic enrichment analysis. Data are plotted as pmol mg−1 of wet tissue weight. At the 2 h time point, hepatic NAD+ (a) shows 54% incorporation of M+1 and M+2 species, indicating that more than half of the NAD+ is turned over before there is a rise in steady-state NAD+. At 2 h, hepatic NADP+ (b) shows 32% incorporation of label(s) from ingested NR. At all time points, half or more of hepatic Nam (c) and MeNam (d) carries an NR-derived label, indicating that NR has driven rapid NAD+ synthesis and consumption. At 2 h after gavage, 45% of hepatic NAAD (e) incorporates NR-derived label(s). At 2 h, hepatic NAD+ (a), NADP+ (b) and NAAD (e) pools incorporate 5, 6 and 8% of double-labelled NR indicating that NR is a direct precursor of all three metabolites and excluding the possibility that the NR-driven increase in NAAD is due to inhibition of de novo synthesis.CC BY · PubMed Central
Figure 8 Dose-dependent effects of NR on the NAD+ metabolome of human subjects. Time-dependent PBMC NAD+ metabolomes from n=12 healthy human subjects were quantified after three different oral doses of NR. In each left panel, the blood concentration of a metabolite as a function of dose and time is displayed (a, NMN; b, NAD+; c, Nam; d, MeNam; e, Me2PY; f, NAAD). #P value<0.05; ##P value<0.01 100 mg versus. 300 mg; ††P value<0.01; †††P value<0.001 100 versus. 1,000; ‡P value<0.05; ‡‡P value<0.01 300 versus. 1,000. A Dunnett's test was performed comparing the average concentration of each metabolite at each time point to the concentration of that metabolite at time zero. Significant elevations of NAD+, MeNam, Me2PY and NAAD are indicated. In each middle panel, the averaged maximum metabolite concentration per dose is plotted. In each right panel, the background-subtracted metabolite AUCs are displayed with a one sample t-test comparing the AUC to background above each bar. In addition, asterisks indicate dose-dependent increases in metabolite AUC (*P value<0.05; **P value<0.01; ***P value<0.001). The data indicate that all doses of NR elevated 8 h NAAD and 24 h NAD+, and that additional NAD+ metabolites were elevated dose dependently with statistical significance by multiple comparisons.
Figure 8 Dose-dependent effects of NR on the NAD+ metabolome of human subjects. Time-dependent PBMC NAD+ metabolomes from n=12 healthy human subjects were quantified after three different oral doses of NR. In each left panel, the blood concentration of a metabolite as a function of dose and time is displayed (a, NMN; b, NAD+; c, Nam; d, MeNam; e, Me2PY; f, NAAD). #P value<0.05; ##P value<0.01 100 mg versus. 300 mg; ††P value<0.01; †††P value<0.001 100 versus. 1,000; ‡P value<0.05; ‡‡P value<0.01 300 versus. 1,000. A Dunnett's test was performed comparing the average concentration of each metabolite at each time point to the concentration of that metabolite at time zero. Significant elevations of NAD+, MeNam, Me2PY and NAAD are indicated. In each middle panel, the averaged maximum metabolite concentration per dose is plotted. In each right panel, the background-subtracted metabolite AUCs are displayed with a one sample t-test comparing the AUC to background above each bar. In addition, asterisks indicate dose-dependent increases in metabolite AUC (*P value<0.05; **P value<0.01; ***P value<0.001). The data indicate that all doses of NR elevated 8 h NAAD and 24 h NAD+, and that additional NAD+ metabolites were elevated dose dependently with statistical significance by multiple comparisons.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 1

  1. Altman, L. K. Who Goes First: The Story of Self-experimentation in Medicine University of California Press (1987).

Cited by

See all 697

Metadata

Authors
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C.
Affiliations
  • University of Iowa (US)
  • Queen's University Belfast (GB)
  • ChromaDex (United States) (US)
Corresponding author
Brenner, Charles
Venue
Nature Communications
Published
2016-10-10
Volume
7
Issue
1
Pages
12948-12948
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2530388030
Cited by
697
References
57
Citations by year
2026: 73 · 2025: 72 · 2024: 63 · 2023: 73 · 2022: 80 · 2021: 89 · 2020: 73 · 2019: 70 · 2018: 58 · 2017: 40 · 2016: 2
FWCI
32.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
Funders
  • Roy J. Carver Charitable Trust
  • National Institutes of Health
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council (BB/N001842/1)
  • National Institute on Alcohol Abuse and Alcoholism (R21AA022371)
  • National Heart, Lung, and Blood Institute (R01HL108379)
  • National Institute of General Medical Sciences (T32GM008629)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
nicotinamide riboside, NAD+ metabolism, oral bioavailability, pharmacokinetics, nicotinic acid, nicotinamide, dose-dependent effects
MeSH terms
Administration, Oral, Animals, Biological Availability, Humans, Leukocytes, Mononuclear, Liver, Male, Mice, Inbred C57BL, Middle Aged, NAD, Niacinamide, Pyridinium Compounds, Vitamins, Biomarkers, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.